Propranolol treatment for infantile hemangioma: a case series of sixty-two patients
| Autor: | Lombardi Aa, Zanzucchi M, Boccaletti, M. Marchesi, Tchana B, Gritti A, N. Carano, Cerasoli G, G. Barbato, Stringari G |
|---|---|
| Rok vydání: | 2016 |
| Předmět: |
Male
Bradycardia medicine.medical_specialty Skin Neoplasms Time Factors Visual analogue scale Adrenergic beta-Antagonists lcsh:Surgery Administration Oral Propranolol Hemangioma 03 medical and health sciences 0302 clinical medicine 030225 pediatrics Infantile hemangioma medicine Humans Adverse effect medicine.diagnostic_test business.industry Therapeutic effect lcsh:RJ1-570 Infant lcsh:Pediatrics Magnetic resonance imaging lcsh:RD1-811 medicine.disease Surgery Treatment Outcome Child Preschool 030220 oncology & carcinogenesis Anesthesia Pediatrics Perinatology and Child Health Female medicine.symptom business Infants medicine.drug |
| Zdroj: | La Pediatria Medica e Chirurgica, Vol 38, Iss 2 (2016) |
| ISSN: | 2420-7748 0391-5387 |
| DOI: | 10.4081/pmc.2016.113 |
| Popis: | Infantile hemangiomas (IH) complicated by ulceration, disfigurement, functional impairment or life-threatening conditions need early, safe and effective treatment. This study explores the impact of propranolol on complicated IH. We report our experience of 62 patients treated with oral propranolol for complicated IH. The effect of propranolol was assessed using a score on a visual analogue scale integrated with echo, magnetic resonance or endoscopic findings. The average age at the beginning of the treatment was seven months [standard deviation (SD)±8.9], with a median of four months (range 1-53 months). The average age at the end of the treatment was 15 months (SD±8.4), with a median of 13 months (range 7-59 months). The mean treatment length was eight months (SD±3.2). Oral propranolol was successful in 95.2% of the patients in reducing the volume, the intensity of color and the elevation of IH. Statistically significant improvement of IH volume was observed in the first two months of therapy (P≤0.001), and between the second month and the end of the treatment (P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|